2. Vías de señalización
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

ADC-Related Custom Services

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Nom du produit Effet Pureté Chemical Structure
  • HY-W873634
    TRAP
    TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
    TRAP
  • HY-P5297
    DOTA-CXCR4-L
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-CXCR4-L
  • HY-185120
    ProX1-(SS)-DOTAGA_R
    ProX1-(SS)-DOTAGA_R (Compound 25a) is the unbound radionuclide portion of the radiopharmaceutical and can be used for targeted delivery to diseases characterized by ACP3 expression.
    ProX1-(SS)-DOTAGA_R
  • HY-W749614
    NO2A-Butyne-bis(t-Butyl ester)
    NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.
    NO2A-Butyne-bis(t-Butyl ester)
  • HY-159768A
    DOTAGA.Glu.(FAPi)2
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium-68, lutetium-177 or terbium-161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme.
    DOTAGA.Glu.(FAPi)2
  • HY-164596
    THP(Bz3)-Glu
    THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    THP(Bz3)-Glu
  • HY-164654
    DOTA-PEG10-azide
    		Control
    DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DOTA-PEG10-azide
  • HY-139564
    DOTA Zoledronate
    DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases.
    DOTA Zoledronate
  • HY-P11718
    cFLFLF
    cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with 64Cu-CuCl2 to form cFLFLFKPEG-64Cu. cFLFLFKPEG-64Cu is a neutrophil-specific PET imaging agent.
    cFLFLF
  • HY-W087027A
    Maleimide-NOTA TFA
    Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.
    Maleimide-NOTA TFA
  • HY-164590
    BCN-NODAGA
    BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    BCN-NODAGA
  • HY-P10012
    Pendetide
    Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma. Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pendetide
  • HY-164599
    TA-DOTA
    TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    TA-DOTA
  • HY-185120A
    ProX1-(SS)-DOTAGA
    ProX1-(SS)-DOTAGA (Compound 12b) is the unbound portion of the radionuclide in the compound and can be used for targeted delivery to diseases characterized by ACP3 expression.
    ProX1-(SS)-DOTAGA
  • HY-P99581
    Tabituximab barzuxetan (exclude Y90)
    Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma.
    Tabituximab barzuxetan (exclude Y90)
  • HY-P992430
    OI-3
    OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma.
    OI-3
  • HY-P991922
    AKIR001
    AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [177Lu] radiolabeled AKIR001, namely [177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma.
    AKIR001
  • HY-164575B
    NH2-NODAGA hydrochloride
    NH2-NODAGA hydrochloride is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA hydrochloride can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA hydrochloride
  • HY-164653
    DOTAEt
    DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DOTAEt
  • HY-P10232
    Hynic-toc
    Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging. Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Hynic-toc
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.